Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma
- PMID: 17318549
- DOI: 10.1007/s00259-007-0366-9
Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma
Abstract
Purpose: This study was designed to retrospectively evaluate the diagnostic yield of FDG PET for the diagnosis of recurrent ovarian cancer.
Methods: Eighty FDG PET scans were performed on 55 patients owing to suspicion of relapse, and 45 FDG PET scans were performed on 31 patients who were clinically disease free. PET results were compared with the results of conventional radiological imaging (CIM) and serum CA 125 levels, and related to pathological findings in 54 cases or clinical follow-up in 71 cases.
Results: CIM correctly identified 49 cases with recurrence [sensitivity (SE) 53.3%] ,and there were 27 true negatives [specificity (SP) 81.8%] However, 43 cases were false negative and six were false positive. The positive predictive value (PPV), negative predictive value (NPV) and accuracy (ACC) of CIM were 89%, 38.6% and 60.8%, respectively. FDG PET correctly detected recurrent disease in 80/92 cases (SE 86.9%, p<0.05) and ruled out relapse in 26/33 cases (SP=78.8%). The PPV, NPV and ACC of PET were 91.9%, 68.4% and 84.8%, respectively. Standardised uptake values did not provide additional diagnostic accuracy compared with visual analysis. The CA 125 results showed an SE of 57.6%, an SP of 93.9% and an ACC of 67.2%. In 23 patients with positive serum CA 125 levels, but negative CIM, FDG PET was positive and relapse was confirmed. Furthermore, FDG PET was positive and relapse was confirmed in 11 patients with negative serum CA 125 levels and CIM.
Conclusion: FDG PET may detect recurrent ovarian cancer earlier than CIM, with higher sensitivity and even higher diagnostic accuracy.
Similar articles
-
[F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125].Rev Esp Med Nucl. 2003 Jul-Aug;22(4):217-23. doi: 10.1016/s0212-6982(03)72189-2. Rev Esp Med Nucl. 2003. PMID: 12846945 Review. Spanish.
-
Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities.Clin Nucl Med. 2012 Aug;37(8):e184-8. doi: 10.1097/RLU.0b013e31825b2583. Clin Nucl Med. 2012. PMID: 22785525
-
Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):797-803. doi: 10.1007/s00259-001-0750-9. Epub 2002 Mar 19. Eur J Nucl Med Mol Imaging. 2002. PMID: 12029554 Clinical Trial.
-
Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.Rev Esp Med Nucl Imagen Mol. 2014 Jan-Feb;33(1):22-7. doi: 10.1016/j.remn.2013.06.008. Epub 2013 Aug 13. Rev Esp Med Nucl Imagen Mol. 2014. PMID: 23948509
-
Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma.Nucl Med Commun. 2008 Jul;29(7):636-41. doi: 10.1097/MNM.0b013e3282f813e1. Nucl Med Commun. 2008. PMID: 18528186
Cited by
-
Meta-analysis of the diagnostic value of 18F-FDG PET/CT in the recurrence of epithelial ovarian cancer.Front Oncol. 2022 Nov 7;12:1003465. doi: 10.3389/fonc.2022.1003465. eCollection 2022. Front Oncol. 2022. PMID: 36419900 Free PMC article.
-
The clinical utility of FDG PET/CT among solid organ transplant recipients suspected of malignancy or infection.Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):421-431. doi: 10.1007/s00259-016-3564-5. Epub 2016 Nov 12. Eur J Nucl Med Mol Imaging. 2017. PMID: 27838763 Free PMC article.
-
Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels.Mol Imaging Biol. 2012 Feb;14(1):123-9. doi: 10.1007/s11307-010-0468-9. Mol Imaging Biol. 2012. PMID: 21240639
-
Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.J Ovarian Res. 2017 Mar 11;10(1):14. doi: 10.1186/s13048-017-0310-y. J Ovarian Res. 2017. PMID: 28284216 Free PMC article.
-
Role of biomarkers for early detection of ovarian cancer recurrence.Gland Surg. 2020 Aug;9(4):1102-1111. doi: 10.21037/gs-20-544. Gland Surg. 2020. PMID: 32953625 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials